Yohimbe (Herb/Suppl)

Brand and Other Names:aphrodien, corynanthe yohimbi, more...corynine, johimbi, pausinystalia yohimbe, quebrachine

Suggested Dosing

Sexual Dysfunction

15-30 mg PO daily

Bark tincture: 5-10 gtt PO TID

Yohimbe bark: Potential for side effects

Numerous regimens available, follow mfct recommendations

Next:

Suggested Uses

Erectile dysfunction, sexual dysfunction (male or female), sexual dysfunction (SSRI-induced)

Efficacy

Possibly effective for impotence

Previous
Next:

Interactions

Interaction Checker

and Yohimbe

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (58)

              • alfuzosin

                yohimbe increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated.

              • amitriptyline

                yohimbe, amitriptyline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • amoxapine

                yohimbe, amoxapine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • asenapine

                yohimbe increases effects of asenapine by pharmacodynamic synergism. Contraindicated.

              • benzphetamine

                yohimbe, benzphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • chlorpromazine

                yohimbe decreases effects of chlorpromazine by pharmacodynamic antagonism. Contraindicated.

              • clomipramine

                yohimbe, clomipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • clonidine

                yohimbe decreases effects of clonidine by pharmacodynamic antagonism. Contraindicated.

              • desipramine

                yohimbe, desipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • dexfenfluramine

                yohimbe, dexfenfluramine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • dexmethylphenidate

                yohimbe, dexmethylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • dextroamphetamine

                yohimbe, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • diethylpropion

                yohimbe, diethylpropion. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • dobutamine

                yohimbe, dobutamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • dopamine

                yohimbe, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • dosulepin

                yohimbe, dosulepin. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • doxazosin

                yohimbe increases effects of doxazosin by pharmacodynamic synergism. Contraindicated.

              • doxepin

                yohimbe, doxepin. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • ephedrine

                yohimbe, ephedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • epinephrine

                yohimbe, epinephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • fenfluramine

                yohimbe, fenfluramine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • fluphenazine

                yohimbe decreases effects of fluphenazine by pharmacodynamic antagonism. Contraindicated.

              • imipramine

                yohimbe, imipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • isoproterenol

                yohimbe, isoproterenol. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • lisdexamfetamine

                yohimbe, lisdexamfetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • lofepramine

                yohimbe, lofepramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • maprotiline

                yohimbe, maprotiline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • methamphetamine

                yohimbe, methamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • methylenedioxymethamphetamine

                yohimbe, methylenedioxymethamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • methylphenidate

                yohimbe, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • midodrine

                yohimbe, midodrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • moxisylyte

                yohimbe increases effects of moxisylyte by pharmacodynamic synergism. Contraindicated.

              • norepinephrine

                yohimbe, norepinephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • nortriptyline

                yohimbe, nortriptyline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • perphenazine

                yohimbe decreases effects of perphenazine by pharmacodynamic antagonism. Contraindicated.

              • phendimetrazine

                yohimbe, phendimetrazine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • phenoxybenzamine

                yohimbe increases effects of phenoxybenzamine by pharmacodynamic synergism. Contraindicated.

              • phentermine

                yohimbe, phentermine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • phentolamine

                yohimbe increases effects of phentolamine by pharmacodynamic synergism. Contraindicated.

              • phenylephrine

                yohimbe, phenylephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • phenylephrine PO

                yohimbe, phenylephrine PO. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • prazosin

                yohimbe increases effects of prazosin by pharmacodynamic synergism. Contraindicated.

              • prochlorperazine

                yohimbe decreases effects of prochlorperazine by pharmacodynamic antagonism. Contraindicated.

              • promazine

                yohimbe decreases effects of promazine by pharmacodynamic antagonism. Contraindicated.

              • promethazine

                yohimbe decreases effects of promethazine by pharmacodynamic antagonism. Contraindicated.

              • propylhexedrine

                yohimbe, propylhexedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • protriptyline

                yohimbe, protriptyline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • serdexmethylphenidate/dexmethylphenidate

                yohimbe, serdexmethylphenidate/dexmethylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • silodosin

                yohimbe increases effects of silodosin by pharmacodynamic synergism. Contraindicated.

              • terazosin

                yohimbe increases effects of terazosin by pharmacodynamic synergism. Contraindicated.

              • thioridazine

                yohimbe decreases effects of thioridazine by pharmacodynamic antagonism. Contraindicated.

              • trazodone

                yohimbe, trazodone. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • trifluoperazine

                yohimbe decreases effects of trifluoperazine by pharmacodynamic antagonism. Contraindicated.

              • trimipramine

                yohimbe, trimipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

              • tyramine

                yohimbe, tyramine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Tyramine containing foods include cheese, red wine, caviar, herring, canned figs, fermented meats, fava beans, yeast extracts, miso, avocado.

              • xylometazoline

                yohimbe, xylometazoline. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • yohimbine

                yohimbe, yohimbine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • zotepine

                yohimbe increases effects of zotepine by pharmacodynamic synergism. Contraindicated.

              Monitor Closely (5)

              • isocarboxazid

                yohimbe increases effects of isocarboxazid by pharmacodynamic synergism. Use Caution/Monitor.

              • linezolid

                yohimbe increases effects of linezolid by pharmacodynamic synergism. Use Caution/Monitor.

              • phenelzine

                yohimbe increases effects of phenelzine by pharmacodynamic synergism. Use Caution/Monitor.

              • procarbazine

                yohimbe increases effects of procarbazine by pharmacodynamic synergism. Use Caution/Monitor.

              • tranylcypromine

                yohimbe increases effects of tranylcypromine by pharmacodynamic synergism. Use Caution/Monitor.

              Minor (16)

              • acebutolol

                acebutolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • atenolol

                atenolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • betaxolol

                betaxolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • bisoprolol

                bisoprolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • carvedilol

                carvedilol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • celiprolol

                celiprolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • esmolol

                esmolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • labetalol

                labetalol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • metoprolol

                metoprolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • nadolol

                nadolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • nebivolol

                nebivolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • penbutolol

                penbutolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • pindolol

                pindolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • propranolol

                propranolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • sotalol

                sotalol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              • timolol

                timolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Anxiety, cardiac coduction disturbances, cardiac failure, dizziness, excitation, fluid retention, gastric intolerance, headache, hypertension, hypotension, insomnia, irritability, nausea/vomiting, paralysis, respiratory depression, salivation, sinusitis, tachycardia, tremor, urinary frequency

              Previous
              Next:

              Warnings

              Contraindications

              Angina, anxiety, BPH, concomitant MAO inhibitors, concomitant sympathomimetic drugs, depression, diabetes mellitus, heart disease, hypertension, hypotension, kidney disease, liver disease, post-traumatic stress disorder, prostate inflammation, tyramine-containing foods

              Cautions

              Schizophrenia

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: unsafe

              Lactation: avoid use

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Metabolism: N/A

              Excretion: N/A

              Mechanism of Action

              Yohimbine is an alpha-2-adrenergic blocker

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.